Source: Annual Congress 2002 - Pathophysiology of interstitial and vascular lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. A. Kogan, V. V. Dengin, G. Jaques, T. Y. Manuilova, N. B. Paramonova (Moscow, Russia; Marburg, Germany). Idiopathic fibrosing alveolitis (IFA) as a background for the lung cancer development. Eur Respir J 2002; 20: Suppl. 38, 3019

Member's Comments

No comment yet.

Related content which might interest you: Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002 Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001 Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 Lung cancer in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD) Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005 Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Histopathological findings of biopsies from patients with extrinsic allergic alveolitis (hipersensitivity pneumonia) in subacute or chronic phase Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD) Source: Eur Respir J 2004; 24: Suppl. 48, 533s Year: 2004 Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Source: Eur Respir J 2011; 38: 384-391 Year: 2011 Clinical and molecular analysis of lung cancer associated with fibrosing and diffuse interstitial lung disease. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 The prevalence of bronchogenic lung cancer (BLC) in patients with idiopathic pneumonic fibrosis (IPF) Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: 43S-55S Year: 2001